Astellas Discontinues Development of SGLT-2 Inhibitor Ipragliflozin in Europe, US; Development in Japan to Go Forward

Astellas Pharma announced on November 1 that it will discontinue development of the SGLT-2 inhibitor ipragliflozin in Europe and the US. Clinical development was in PII in Europe and the US, but the company decided to discontinue development due to...read more